Cortechs.ai | A word from the CEO: 2014 in review

A word from the CEO: 2014 in review

2014 was an amazing year at Cortechs.ai. We experienced remarkable growth in all aspects of the company and added many significant hospitals, clinics, universities, imaging service facilities and military bases as customers. I want to warmly thank you for using NeuroQuant in your clinical and research practices.

In my role as the CEO of Cortechs.ai, I get many opportunities to speak with a range of customers – from the neurology and neuroradiology heads of the largest hospitals and clinics, to the smallest imaging services facilities, in the US and in Europe. It is always a great opportunity for me to get a first-hand impression of the state-of-the-art trends in radiology and neurology and to sense the reality and daily challenges of providing imaging healthcare services.

What I have learned this year is that quantitative imaging is getting acceptance in clinical practice and that measuring sub-cortical brain volumes and comparing them to normative values has clinical application in a growing number of clinical disciplines, from dementia, through epilepsy, multiple sclerosis, traumatic brain injuries and a variety of pediatric disorders.

Armed with great customer feedback and with growth momentum, we are getting ready to improve NeuroQuant even further to keep its leading position in the T1-weighted quantitative imaging market. This year NeuroQuant customer will enjoy a much broader set of reports highlighting more brain volumes that are relevant to the above clinical disciplines.  Additionally, we will further improve scan/re-scan accuracy, computational performance and the support of additional platforms such as Windows and Linux.

As usual, we always look for feedback and ideas for improvement and we welcome anybody that wants to share it with us.

I would like to invite you to our website (cortechs.ai) where you will find a wealth of information and scientific publications relevant to quantitative imaging.

Whether you are looking to learn and educate yourself about quantitative neuroimaging, or if you want to hear how to use it in clinical practice – we can help. Feel free to contact us.

Guri Stark
CEO
Cortechs.ai

More Resources

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.

02/24/2026

Financial Conflict Of Interest Policy Applicable To NIH Awards

02/20/2026

NeuroQuant® PET: FDA 510(k)-Pending Advancement in Molecular Dementia Imaging

FDA 510(k)-Pending NeuroQuant® PET delivers automated, standardized quantification for amyloid, tau, and FDG imaging in dementia care.

02/19/2026

How Cortechs.ai Protects ePHI: HIPAA‑Aligned Controls—and Beyond

Cortechs.ai’s HIPAA-aligned, defense-in-depth security safeguards ePHI across AI workflows—exceeding baseline compliance standards.
Scroll to Top